Qube Research & Technologies LTD Rhythm Pharmaceuticals, Inc. Transaction History

Qube Research & Technologies LTD

$82.3 Billion
Q1 2025

A detailed history of Qube Research & Technologies LTD transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 216,193 shares of RYTM stock, worth $14.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

216,193

Previous 95,235 127.01%

Holding current value

$14.2 Million

Previous $5.32 Million 115.12%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$48.56 - $61.02 $5.87 Million - $7.38 Million	120,958 Added 127.01%	216,193 $11.5 Million
Q4 2024 Feb 14, 2025	BUY	$46.91 - $67.33 $4.47 Million - $6.41 Million	95,235 New	95,235 $5.32 Million
Q1 2023 May 15, 2023	BUY	$16.88 - $34.24 $1.87 Million - $3.79 Million	110,757 Added 61.34%	291,314 $5.2 Million
Q4 2022 Feb 14, 2023	BUY	$22.21 - $30.25 $4.01 Million - $5.46 Million	180,557 New	180,557 $5.26 Million
Q2 2022 Aug 15, 2022	BUY	$3.12 - $12.25 $89,837 - $352,726	28,794 New	28,794 $119,000
Q4 2021 Feb 01, 2022	SELL	$8.62 - $13.9 $133,204 - $214,796	-15,453 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$11.68 - $20.72 $90,765 - $161,015	-7,771 Reduced 33.46%	15,453 $202,000
Q2 2021 Aug 13, 2021	SELL	$18.52 - $22.55 $63,931 - $77,842	-3,452 Reduced 12.94%	23,224 $455,000
Q1 2021 May 14, 2021	BUY	$20.25 - $39.49 $540,189 - $1.05 Million	26,676 New	26,676 $567,000
Q4 2020 Feb 16, 2021	SELL	$21.17 - $32.61 $321,424 - $495,117	-15,183 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$18.13 - $30.61 $275,267 - $464,751	15,183 New	15,183 $329,000

Others Institutions Holding RYTM

# of Institutions

245

Shares Held

62.9M

Call Options Held

403K

Put Options Held

62.8K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.66B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Account

Qube Research & Technologies LTD Rhythm Pharmaceuticals, Inc. Transaction History